EPLIN, a marker for human Cancer

BACKGROUND: EPLIN, a novel gene not previously described encodes a protein expressed in human epithelial cells. EPLIN is of significant importance because its expression is diminished in many forms of human cancers including breast and prostate cancer. Restoring the expression of EPLIN in cancer cells antagonizes oncogenic transformation.

DESCRIPTION: UC researchers have discovered a gene encoding EPLIN. EPLIN cDNA has been cloned, completely sequenced, and tested to detect its expression in human cells and tissues. The EPLIN gene has been cloned to determine the structure of the EPLIN gene including the regulatory sequences for the expression of EPLIN. In addition, EPLIN has been bacterially expressed to generate polyclonal antibodies to detect the expression of EPLIN by immunoblotting, immunohistochemistry, and in situ immunofluorescence.

APPLICATIONS: EPLIN-based molecular reagents can be used in cancer detection, prognosis, and therapy. The EPLIN gene can be used to determine how the expression of EPLIN is down-regulated in cancer cells.

ADVANTAGES:

* EPLIN-based molecular reagents will prove useful because there are a limited number of biomarkers with proven utility for detection of breast and prostate cancer.
* EPLIN-based biomarkers can be used in conjunction with or independently of existing biomarkers to facilitate the diagnosis and prognosis of these cancers.

REFERENCE: 1999-300

Patents:
US 6,864,066   [MORE INFO]

Type of Offer: Licensing



« More Genetics Patents
« More Pharmaceutical Patents

---